Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge
Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembro...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2019.02.008 |
| _version_ | 1826936718061731840 |
|---|---|
| author | Sara De Dosso |
| author_facet | Sara De Dosso |
| author_sort | Sara De Dosso |
| collection | DOAJ |
| description | Gastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembrolizumab, for instance, has been approved in the USA in 2017, with the indication of advanced gastric and esophageal programmed death-ligand 1 (PD-L1)-positive tumors, as well as for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) solid tumors.^1,2^
Signals of outstanding efficacy were particularly observed in biomarker selected populations.^3^ Hence, there is an urgent need to identify precise predictive biomarkers for optimal patient selection and to establish more effective treatment timings.
The present review summarizes the current clinical evidence supporting treatment with ICIs in upper GI tumors. |
| first_indexed | 2024-04-24T22:27:08Z |
| format | Article |
| id | doaj.art-6171bd2cd32f4166a607c376ad5efbe5 |
| institution | Directory Open Access Journal |
| issn | 2673-2106 |
| language | English |
| last_indexed | 2025-02-17T18:26:28Z |
| publishDate | 2019-12-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj.art-6171bd2cd32f4166a607c376ad5efbe52024-12-12T17:11:14ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-21062019-12-0122Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current KnowledgeSara De DossoGastroesophageal cancers have a poor prognosis despite the use of novel therapies, such as chemotherapy combinations and biologic agents. Recently, immune checkpoint inhibitors (ICIs) have also been introduced into the treatment landscape. The programmed cell death protein 1 (PD-1) inhibitor, pembrolizumab, for instance, has been approved in the USA in 2017, with the indication of advanced gastric and esophageal programmed death-ligand 1 (PD-L1)-positive tumors, as well as for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) solid tumors.^1,2^ Signals of outstanding efficacy were particularly observed in biomarker selected populations.^3^ Hence, there is an urgent need to identify precise predictive biomarkers for optimal patient selection and to establish more effective treatment timings. The present review summarizes the current clinical evidence supporting treatment with ICIs in upper GI tumors.https://doi.org/10.36000/hbT.OH.2019.02.008 |
| spellingShingle | Sara De Dosso Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge healthbook TIMES. Oncology Hematology |
| title | Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge |
| title_full | Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge |
| title_fullStr | Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge |
| title_full_unstemmed | Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge |
| title_short | Immunotherapy in Advanced Gastroesophageal Tumors: The Best of the Current Knowledge |
| title_sort | immunotherapy in advanced gastroesophageal tumors the best of the current knowledge |
| url | https://doi.org/10.36000/hbT.OH.2019.02.008 |
| work_keys_str_mv | AT saradedosso immunotherapyinadvancedgastroesophagealtumorsthebestofthecurrentknowledge |